Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome + Azacitidine + Venetoclax in Secondary AML
NCT07028086Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone-liposome in acute myeloid leukemia (AML), myeloid sarcoma (MS), sponsored by Ruijin Hospital. Started Jun 2025; status: recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)myeloid sarcoma (MS)
Beyond the preview
Go deeper on NCT07028086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028086.